Evidence map›Paper›PMID 28626375›Full record

ArticleCase reports in gastroenterology

Intravenous Bevacizumab Therapy in a Patient with Hereditary Hemorrhagic Telangiectasia,

Luigi F Bertoli, Pauline L Lee, Lauren Lallone, James C Barton

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Luigi F BertoliDepartment of Medicine, Brookwood Medical Center, Birmingham, Alabama, USA.
Pauline L LeeDepartment of Molecular and Experimental Medicine, The Scripps Research Institute, La Jolla, California, USA.
Lauren LalloneBrookwood Biomedical, Birmingham, Alabama, USA.
James C BartonDepartment of Medicine, Brookwood Medical Center, Birmingham, Alabama, USA.
Brookwood Baptist Health · USScripps Research Institute · USUniversity of Alabama at Birmingham · US

Funding

HEMOCHROMATOSIS--EPIDEMIOLOGY AND MOLECULAR MECHANISMSR01DK053505 · NIDDK · SCRIPPS RESEARCH INSTITUTE, THE · PI LEE, PAULINE L · 1998 to 2010
$7.8M
NIDDK NIH HHS R01 DK053505
6 · The paper itself

Abstract

Intravenous bevacizumab decreased mucosal bleeding in some patients with hereditary hemorrhagic telangiectasia (HHT). We treated a 47-year-old male who had HHT, severe epistaxis, and gastrointestinal bleeding, alcoholic cirrhosis, and portal hypertension with intravenous bevacizumab 2.5 mg/kg every 2 weeks. We tabulated these measures weekly during weeks 1-33 (no bevacizumab); 34-57 (bevacizumab); and 58-97 (no bevacizumab): hemoglobin (Hb) levels; platelet counts; units of transfused packed erythrocytes (PRBC units); and quantities of iron infused as iron dextran to support erythropoiesis. We performed univariate and multivariable analyses. We sequenced his

Indexed as

BevacizumabENG E137KHereditary hemorrhagic telangiectasiaIron dextranTransfusionVascular endothelial growth factor

Identifiers

PMID28626375
PMCPMC5471789
OpenAlexW2615020035

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.